Valerio De Stefano
Overview
Explore the profile of Valerio De Stefano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
255
Citations
4197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barbui T, De Stefano V, Rossi E, Ghirardi A, Carobbio A, Loscocco G, et al.
Am J Hematol
. 2025 Mar;
PMID: 40062566
This paper explores emerging therapies in polycythemia vera and essential thrombocythemia, focusing on thrombosis as a driver of disease progression leading to myelofibrosis, blast phase, second cancers, and mortality. While...
2.
Martino E, Pitino A, Offidani M, Pepa R, Gozzetti A, Bongarzoni V, et al.
Haematologica
. 2025 Mar;
PMID: 40045883
Not available.
3.
Fazio F, Gherardini M, Rossi E, Za T, Di Landro F, More S, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941726
Background/objectives: Treatments for multiple myeloma (MM) have expanded in the last decade, and the overall survival (OS) of MM patients (pts) is in continuous improvement. With the availability of new...
4.
Martino E, Derudas D, Rossi E, Stefanoni P, Mangiacavalli S, Zamagni E, et al.
Hematol Oncol
. 2025 Feb;
43(2):e70042.
PMID: 39898517
This multicenter real-world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara-R). The majority were under...
5.
Ramundo F, Rossi E, Peris K, Pontecorvi A, Sani G, Betti S, et al.
Curr Med Res Opin
. 2025 Jan;
41(2):239-245.
PMID: 39882590
Introduction: The management of patients with Polycythemia Vera (PV) traditionally includes low-dose aspirin, phlebotomy, and cytoreductive therapy for high-risk individuals. Recent evidence suggests that cytoreductive treatment may be warranted for...
6.
Maiolo E, Bellesi S, Campana F, Iacovelli C, Malafronte R, Schiaffini G, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682155
CD79b is a B-cell-specific antigen that is crucial to the B-cell receptor and is considered a key target for treatment in aggressive B-cell lymphomas. While immunohistochemical studies have shown widespread...
7.
Martino E, Derudas D, Rossi E, Terlizzi S, Reddiconto G, Stefanoni P, et al.
Haematologica
. 2024 Nov;
PMID: 39605207
Not available.
8.
Barbui T, Ghirardi A, Carobbio A, De Stefano V, Rambaldi A, Tefferi A, et al.
Blood Cancer J
. 2024 Oct;
14(1):188.
PMID: 39455571
This viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs) to assess the impact of thrombosis on mortality, disease progression, and second cancers (SC). Despite...
9.
Barbui T, Carobbio A, Guglielmelli P, Ghirardi A, Fenili F, Loscocco G, et al.
Br J Haematol
. 2024 Oct;
205(6):2287-2294.
PMID: 39375955
We investigated the effect of Ropeginterferon alfa-2b (Ropeg) versus phlebotomy-only (Phl-O) on the neutrophil-to-lymphocyte ratio (NLR) in 126 patients randomized in the low-polycythaemia vera (PV) phase II trial. Patients with...
10.
Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al.
Leukemia
. 2024 Sep;
38(12):2554-2560.
PMID: 39322709
Treatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of...